Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

BMC Cancer

Volumn 9, Issue , 2009, Pages 339-

  Kostopoulos, Ioannis ^a   Karavasilis, Vasilios ^a   Karina, Maria ^a   Bobos, Mattheos ^a   Xiros, Nikolaos ^b   Pentheroudakis, George ^c   Kafiri, Georgia ^d   Papakostas, Pavlos ^d   Vrettou, Eleni ^a   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d Ippokration Hospital Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COLON RESECTION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 70449360930     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-339     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310. 10.1053/j.gastro.2008.02.098, 2528832, 18471507.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995, 13:2936-2943.
4. Cunningham D, Starling N. Adjuvant chemotherapy of colorectal cancer. Lancet 2007, 370:1980-1981. 10.1016/S0140-6736(07)61841-8, 18083386.
5. Midgley R, Kerr DJ. Adjuvant chemotherapy for stage II colorectal cancer: the time is right!. Nat Clin Pract Oncol 2005, 2:364-369. 10.1038/ncpuro0253, 16075796.
6. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005, 23:2020-2027. 10.1200/JCO.2005.01.112, 15774793.
7. Elsaleh H, Shannon B, Iacopetta B. Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy. Gastroenterology 2001, 120:1309-1310. 10.1053/gast.2001.23646, 11288748.
8. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257. 10.1056/NEJMoa022289, 12867608.
9. Van TB, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000, 11:385-391. 10.1023/A:1008351221345, 10847455.
10. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008, 19:915-919. 10.1093/annonc/mdm599, 18245778.
11. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995, 1262:1-14.
12. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 1996, 50:1095-1102.
13. Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002, 33:1114-1119. 10.1053/hupa.2002.129202, 12454816.
14. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004, 111:252-258. 10.1002/ijc.20208, 15197779.
15. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 2000, 58:227-236. 10.1159/000012105, 10765125.
16. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Liaros A. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999, 10:671-676. 10.1023/A:1008357609434, 10442189.
17. Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study. Eur J Cancer 2008, 44:1693-1700. 10.1016/j.ejca.2008.05.025, 18639450.
18. Kalofonos HP, Kardamakis D, Bamias A, Skarlos D, Papakostas P, Bafaloukos D. Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study. Anticancer Res 2003, 23:1687-1691.
19. Papakostas P, Kalofonos HP, Pentheroudakis G, Timotheadou E, Papadimitriou C, Tsavdaridis D. Safety results of a phase III randomised trial of adjuvant treatment with 5-fluorouracil and folinic acid with or without irinotecan, in Dukes B2 and C colon cancer. J Clin Oncol 2007, 25(June 20 Supplement).
20. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002, 20:1735-1743. 10.1200/JCO.2002.07.080, 11919229.
21. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998, 4:1243-1250.
22. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999, 17:1760-1770.
23. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999, 5:1996-1999.
24. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004, 22:529-536. 10.1200/JCO.2004.05.064, 14752076.
25. Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006, 17:1810-1817. 10.1093/annonc/mdl301, 16971666.
26. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003, 9:4116-4124.
27. Jensen SA, Vainer B, Witton CJ, Jorgensen JT, Sorensen JB. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncol 2008, 47:1054-1061. 10.1080/02841860801942158, 18607850.
28. van TB, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000, 6:1063-1072.
29. Tsunoda T, Tanimura H, Hotta T, Tani M, Iwahashi M, Tanaka H. In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer. Anticancer Res 1999, 19:5451-5455.
30. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999, 80:364-370. 10.1038/sj.bjc.6690364, 2362335, 10408839.
31. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125. 10.1200/JCO.2008.21.6663, 19451425.
32. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26:2690-2698. 10.1200/JCO.2007.15.5580, 18509181.